Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Wells Fargo & Co — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Wells Fargo & Co trades at $83.55 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 19.7× Halozyme Therapeutics Inc. Common Stock's market cap, and Wells Fargo & Co pays a 2.44% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Wells Fargo & Co for 88 Days on average.
| HALO | WFC | |
|---|---|---|
Market Cap | $12.58B | $248.06B |
Volume | 2,179,278 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $115.22 | $96.40 |
52-Week Low | $61.63 | $73.42 |
Typical Hold Time | 1 Days | 88 Days |
Enterprise Value | $14.49B | $503.91B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wells Fargo (WFC) trades at $83.55, up 4.1% today, showing strong momentum despite a bearish technical signal. The stock offers attractive valuation with P/E of 11.92 and P/B of 1.5, supported by improving profitability with net margin reaching 25.97% in 2025. Recent positive developments include a credit rating upgrade to 'A-' by S&P and upcoming Q3 2026 earnings on October 13th. The company maintains solid fundamentals with $21.34B net income and 13.13% ROE, though cash flow volatility remains a concern.
WFC presents a compelling value opportunity with analyst consensus target of $99.13 (18.6% upside) and strong institutional support. However, investors face risks from inconsistent earnings performance (two recent misses), regulatory uncertainty from Fed stress test changes, and volatile cash flow patterns. The stock's technical weakness contrasts with fundamental strength, creating potential for convergence if upcoming earnings beat expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
